Drug Trial Radar · NCT00231738
Protective Effect of EPA on Cardiovascular Events
Last checked: Nov 20, 2026Latest source record: Nov 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18,000
Actual
Start
Nov 1996
Primary completion
Not stated
Study completion Nov 2004
Sponsor
- Lead sponsor
- Kobe UniversityIndustry
- Sponsor type
- Industry
- Collaborators
- Mochida Pharmaceutical Company, Ltd.
- First posted
- Oct 4, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to test the hypothesis that the long-term use of highly (\>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.
Conditions
- Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease
Interventions
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major coronary events (sudden cardiac death, fatal and nonfatal myocardial infarction, unstable angina pectoris including hospitalization for ischemic episodes,events of angioplasty/ stenting or coronary artery bypass grafting)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kobe University Graduate School of Medicine Cardiovascular and Respiratory Medicine Division, Department of Internal Medicine
Kobe, Hyōgo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.